Anthem Biosciences Q1 FY27 Results: Margins Improve Despite Revenue Decline; Strong Balance Sheet Supports Growth Outlook

What Happened ?

key details

Financial Performance:

• Revenue from Operations declined 22.6% YoY to ₹4,182 million.
• Total Revenue stood at ₹4,431 million, down 21.3% YoY.
• EBITDA was ₹1,755 million, with EBITDA Margin improving to 39.6% from 38.1% in Q1 FY26.
• Profit Before Tax (PBT) came in at ₹1,446 million.
• Profit After Tax (PAT) stood at ₹1,199 million, while PAT Margin improved to 27.1% from 24.1% a year ago.
• Margin expansion was supported by operational efficiencies, better cost control and productivity improvements despite lower revenues.

Note:

• Although quarterly revenues moderated because of shipment timing, Anthem Biosciences continued to improve profitability through disciplined execution and efficient cost management.

CRDMO Business:

• CRDMO revenue: ₹3,408 million.
• Contributed 81.5% of total operating revenue.
• Commercial manufacturing portfolio expanded to 14 commercial molecules.
• Late-stage development pipeline comprised 10 Phase III molecules.
• Continued to witness healthy customer engagement across innovator pharmaceutical companies.

Note:

• The CRDMO segment remains the company’s primary business, supported by a diversified customer base, long-term contracts and a robust development pipeline expected to drive future commercial manufacturing opportunities.

Specialty Ingredients Business:

During Q1 FY27, the company executed several strategic initiatives.

• Revenue stood at ₹774 million.
• Contributed 18.5% of total operating revenue.
• Performance was impacted by the timing of customer deliveries during the quarter.
• Business continues to benefit from diversified product offerings across fermentation-based and synthetic specialty ingredients.

Note:

• Management indicated that the quarterly decline was primarily timing-related rather than demand-driven, with deliveries expected to normalize in the coming quarters. 

Manufacturing & Capacity:

The company continues to strengthen its manufacturing platform.

• Custom Synthesis Capacity: 425 KL
• Fermentation Capacity: 142 KL
• Manufacturing infrastructure supports both clinical and commercial-scale production.
• Continued investments in process development, technology transfer and manufacturing excellence.

Note:

• Anthem’s integrated manufacturing capabilities across custom synthesis and fermentation remain key differentiators in serving global pharmaceutical customers. 

Balance Sheet & Financial Position:

• Net Cash: ₹17.2 billion
• Post-tax ROCE: 23.3%
• Return on Equity (ROE): 15.4%
• Gross Fixed Asset Turnover: 1.10x
• Net Cash to Annualised EBITDA: 2.45x

Note:

• The company’s debt-free balance sheet and significant cash reserves provide financial flexibility for future capacity expansion, strategic investments and business development initiatives. 

Business Outlook:

Management expects business momentum to improve during the remainder of FY27, supported by:

• Scheduled customer deliveries shifting into subsequent quarters.
• Healthy pipeline of commercial and late-stage molecules.
• Continued growth opportunities in the global CRDMO market.
• Increasing demand for integrated development and manufacturing services.
• Ongoing investments in manufacturing capacity and operational capabilities.

Note:

• While Q1 reflected temporary shipment timing impacts, the underlying business fundamentals and long-term growth drivers remain intact according to management. 

Risk Analysis

Summary:

• Anthem Biosciences’ Q1 FY27 performance was impacted primarily by the timing of customer deliveries rather than structural weakness in demand. The company continues to maintain strong profitability, a healthy CRDMO pipeline and a debt-free balance sheet. However, future performance will depend on execution of scheduled deliveries, customer project progression and sustained demand from global pharmaceutical innovators.

Key Risks:

• Revenue remains susceptible to timing differences in customer deliveries, particularly in the CRDMO business.
• Delays in clinical development or commercialization of customer molecules could affect future manufacturing revenue.
• The company operates in a highly regulated pharmaceutical manufacturing environment where regulatory compliance remains critical.
• Expansion projects and capacity additions require timely execution to support future growth.
• Currency fluctuations and changes in global pharmaceutical spending may influence export revenues.
• Increasing competition within the global CRDMO industry could exert pressure on pricing and new customer acquisition.

Worst Case:

• If customer delivery schedules continue to shift, late-stage clinical programs are delayed, or commercial manufacturing demand weakens, revenue growth could remain subdued despite maintaining strong operating margins and a healthy order pipeline.

Risk Level: Medium

Company Commentary

• Management stated that the softer Q1 FY27 performance was primarily due to the timing of customer deliveriesrather than any deterioration in business demand.
• The company highlighted that profitability remained resilient, with both EBITDA Margin and PAT Marginimproving despite lower revenues.
• Anthem Biosciences continues to witness a healthy pipeline across both commercial manufacturing and late-stage development programs, reinforcing long-term growth visibility.
• Management remains confident of stronger business momentum during the second half of FY27, supported by deferred customer shipments and sustained demand across the CRDMO business.
• The company reiterated its commitment to investing in manufacturing capacity, operational excellence and technology capabilities while maintaining a strong balance sheet to support future growth initiatives.